immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.
Company profile
Ticker
IMCR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Amgen • GE Vernova • Gilead Sciences • Apollo Global Management • ADT • Informatica • NIO • Opendoor • GoHealth • BrightSphere Investment ...
Former names
Immunocore Ltd
SEC CIK
Corporate docs
Subsidiaries
Immunocore Limited • Immunocore LLC • Immunocore Commercial LLC • Immunocore Ireland Limited • Immunocore GmbH • Immunocore Nominees Limited ...
IMCR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
16 Sep 24
8-K
Immunocore announces transition of Chief Financial Officer
29 Aug 24
8-K
Immunocore reports second quarter financial results and provides a business update
8 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Regulation FD Disclosure
31 May 24
8-K
Other Events
30 May 24
8-K
Entry into a Material Definitive Agreement
28 May 24
8-K
Submission of Matters to a Vote of Security Holders
23 May 24
8-K
Immunocore reports first quarter financial results and provides a business update
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
Latest ownership filings
SC 13G
T. Rowe Price Investment Management, Inc.
10 Sep 24
4
JULIAN BAKER
29 May 24
3
RANJEEV KRISHANA
29 May 24
3
JULIAN BAKER
29 May 24
4
Siddharth Kaul
28 May 24
4
Peter John Ratcliffe
28 May 24
4
Kristine Peterson
28 May 24
4
Roy Steven Herbst
28 May 24
4
John Irving Bell
28 May 24
4
Leger Tina Amber St
3 Apr 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 504.99 mm | 504.99 mm | 504.99 mm | 504.99 mm | 504.99 mm | |
Cash burn (monthly) | 109.28 mm | 27.32 mm | 5.34 mm | 3.54 mm | 382.25 k | |
Cash used (since last report) | 410.35 mm | 102.59 mm | 20.05 mm | 13.30 mm | 1.44 mm | |
Cash remaining | 94.64 mm | 402.40 mm | 484.94 mm | 491.68 mm | 503.55 mm | |
Runway (months of cash) | 0.9 | 14.7 | 90.8 | 138.8 | 1317.3 |
Institutional ownership, Q2 2024
4.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 111.40 mm |
Total shares | 2.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Malin Life Sciences | 2.11 mm | $111.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 May 24 | Baker Bros. Advisors | Non-Qualified Share Option Ordinary Shares | Grant | Acquire A | Yes | No | 46.05 | 12,925 | 595.20 k | 12,925 |
28 May 24 | Baker Bros. Advisors | Non-Qualified Share Option Ordinary Shares | Grant | Acquire A | Yes | No | 46.05 | 12,925 | 595.20 k | 12,925 |
23 May 24 | Peter John Ratcliffe | Share Option Ordinary Shares | Grant | Acquire A | No | No | 50.47 | 14,534 | 733.53 k | 14,534 |
23 May 24 | Kristine Peterson | Share Option Ordinary Shares | Grant | Acquire A | No | No | 50.47 | 14,534 | 733.53 k | 14,534 |
News
Morgan Stanley Maintains Overweight on Immunocore Hldgs, Lowers Price Target to $74
11 Oct 24
Analyst Ratings For Immunocore Hldgs
7 Oct 24
Guggenheim Downgrades Immunocore Hldgs to Neutral
7 Oct 24
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
17 Sep 24
Analyst Expectations For Immunocore Hldgs's Future
17 Sep 24